It is estimated that half a million Australians are now using GLP-1 drugs, and demand has risen sharply through private prescriptions.

Moreover, these drugs, including treatments such as Ozempic, Wegovy and Mounjaro, are used to treat type 2 diabetes and weight management.

Furthermore, a large number of users access the drugs outside of government subsidies, with many paying privately.

Health experts say the rapid growth in use of these drugs highlights the need for medical supervision and awareness of potential side effects.

Australia’s medicines regulator has also issued a safety update on rare but serious risks associated with GLP-1 drugs, advising patients to seek medical advice if they experience symptoms.